These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11605967)

  • 1. Emerging pollutants, and communicating the science of environmental chemistry and mass spectrometry: pharmaceuticals in the environment.
    Daughton CG
    J Am Soc Mass Spectrom; 2001 Oct; 12(10):1067-76. PubMed ID: 11605967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievements and future trends in the analysis of emerging organic contaminants in environmental samples by mass spectrometry and bioanalytical techniques.
    Farré M; Kantiani L; Petrovic M; Pérez S; Barceló D
    J Chromatogr A; 2012 Oct; 1259():86-99. PubMed ID: 22877973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Environmental mass spectrometry: emerging contaminants and current issues.
    Richardson SD
    Anal Chem; 2008 Jun; 80(12):4373-402. PubMed ID: 18498180
    [No Abstract]   [Full Text] [Related]  

  • 4. Human pharmaceutical products in the environment - the "problem" in perspective.
    Taylor D; Senac T
    Chemosphere; 2014 Nov; 115():95-9. PubMed ID: 24525259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Environmental risk analysis and prioritization of pharmaceuticals in a developing world context.
    Mansour F; Al-Hindi M; Saad W; Salam D
    Sci Total Environ; 2016 Jul; 557-558():31-43. PubMed ID: 26994791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals in the environment, a prescription for disaster?
    Agamuthu P; Fauziah SH
    Waste Manag Res; 2011 Apr; 29(4):349-50. PubMed ID: 21444587
    [No Abstract]   [Full Text] [Related]  

  • 7. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process.
    Laenge R; Steger-Hartmann T; Schweinfurth H
    Regul Toxicol Pharmacol; 2006 Aug; 45(3):223-8. PubMed ID: 16716476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental mass spectrometry: emerging contaminants and current issues.
    Richardson SD
    Anal Chem; 2004 Jun; 76(12):3337-63. PubMed ID: 15193112
    [No Abstract]   [Full Text] [Related]  

  • 9. The challenge: do pharmaceuticals present a risk to the environment, and what needs to be done to answer the question?
    Sumpter JP
    Environ Toxicol Chem; 2014 Sep; 33(9):1915. PubMed ID: 25138028
    [No Abstract]   [Full Text] [Related]  

  • 10. International scientists' priorities for research on pharmaceutical and personal care products in the environment.
    Rudd MA; Ankley GT; Boxall AB; Brooks BW
    Integr Environ Assess Manag; 2014 Oct; 10(4):576-87. PubMed ID: 24954797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Matthew Effect and widely prescribed pharmaceuticals lacking environmental monitoring: case study of an exposure-assessment vulnerability.
    Daughton CG
    Sci Total Environ; 2014 Jan; 466-467():315-25. PubMed ID: 23911922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Environmental mass spectrometry: emerging contaminants and current issues.
    Richardson SD
    Anal Chem; 2002 Jun; 74(12):2719-41. PubMed ID: 12090660
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving environmental risk assessment of human pharmaceuticals.
    Ågerstrand M; Berg C; Björlenius B; Breitholtz M; Brunström B; Fick J; Gunnarsson L; Larsson DG; Sumpter JP; Tysklind M; Rudén C
    Environ Sci Technol; 2015 May; 49(9):5336-45. PubMed ID: 25844810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current state-of-the-art in the determination of pharmaceutical residues in environmental matrices using hyphenated techniques.
    Jakimska A; Kot-Wasik A; Namieśnik J
    Crit Rev Anal Chem; 2014; 44(3):277-98. PubMed ID: 25391566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks.
    Celiz MD; Tso J; Aga DS
    Environ Toxicol Chem; 2009 Dec; 28(12):2473-84. PubMed ID: 19663539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to the special issue on environmental risk assessment of pharmaceuticals.
    Knacker T; Metcalfe C
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():511-3. PubMed ID: 20821716
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals in biota in the aquatic environment: analytical methods and environmental implications.
    Huerta B; Rodríguez-Mozaz S; Barceló D
    Anal Bioanal Chem; 2012 Nov; 404(9):2611-24. PubMed ID: 22678760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioaccumulation and analytics of pharmaceutical residues in the environment: A review.
    Puckowski A; Mioduszewska K; Łukaszewicz P; Borecka M; Caban M; Maszkowska J; Stepnowski P
    J Pharm Biomed Anal; 2016 Aug; 127():232-55. PubMed ID: 26968887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental mass spectrometry.
    Lebedev AT
    Annu Rev Anal Chem (Palo Alto Calif); 2013; 6():163-89. PubMed ID: 23527549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why regulatory indifference towards pharmaceutical pollution of the environment could be a missed opportunity in public health protection. a holistic view.
    Kamba PF; Kaggwa B; Munanura EI; Okurut T; Kitutu FE
    Pan Afr Med J; 2017; 27():77. PubMed ID: 28819498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.